## Correction to: Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel

This is a correction to: Bolivar Arboleda, Rupert Bartsch, Evandro de Azambuja, Erika Hamilton, Nadia Harbeck, Jennifer Klemp, Michael Knauer, Sherko Kuemmel, Reshma Mahtani, Lee Schwartzberg, Cynthia Villarreal-Garza, Antonio Wolff, Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel, *The Oncologist*, 2022, oyac101, https://doi.org/10.1093/oncolo/oyac101

Financial disclosures for Reshma L. Mahtani were missing from the Conflict of Interest section of the originally published version of this article. The following disclosures were added before final publication:

Reshma L. Mahtani: Agendia, Amgen, AstraZeneca, Biotheranostics, Daiichi, Eisia, Genentech, Gilead, Lilly, Merck, Novartis, Pfizer, Puma, Sanofi, SeaGen (C/A)

© The Author(s) 2022. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.